MX2019015927A - Composiciones para administración de fármacos y métodos de uso de las mismas. - Google Patents
Composiciones para administración de fármacos y métodos de uso de las mismas.Info
- Publication number
- MX2019015927A MX2019015927A MX2019015927A MX2019015927A MX2019015927A MX 2019015927 A MX2019015927 A MX 2019015927A MX 2019015927 A MX2019015927 A MX 2019015927A MX 2019015927 A MX2019015927 A MX 2019015927A MX 2019015927 A MX2019015927 A MX 2019015927A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- drug delivery
- salt
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000012377 drug delivery Methods 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000000227 bioadhesive Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
- G01N2333/765—Serum albumin, e.g. HSA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
Abstract
Se describe en la presente composiciones para administración vaginal de un agente activo o una sal a un sujeto que comprende el agente activo o sal del mismo, un bioadhesivo, y una emulsión. También se describen en la presente métodos para tratar una enfermedad o afección al administrar vaginalmente a un sujeto una composición farmacéutica, y kits que comprende la composición farmacéutica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762523510P | 2017-06-22 | 2017-06-22 | |
PCT/IB2018/000807 WO2018234871A2 (en) | 2017-06-22 | 2018-06-22 | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019015927A true MX2019015927A (es) | 2020-08-06 |
Family
ID=63405247
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019015927A MX2019015927A (es) | 2017-06-22 | 2018-06-22 | Composiciones para administración de fármacos y métodos de uso de las mismas. |
MX2023006235A MX2023006235A (es) | 2017-06-22 | 2019-12-20 | Composiciones para administracion de farmacos y metodos de uso de las mismas. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023006235A MX2023006235A (es) | 2017-06-22 | 2019-12-20 | Composiciones para administracion de farmacos y metodos de uso de las mismas. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20200121589A1 (es) |
EP (1) | EP3641821A2 (es) |
JP (2) | JP7345398B2 (es) |
KR (1) | KR20200019735A (es) |
CN (1) | CN111386129A (es) |
AU (1) | AU2018287513A1 (es) |
BR (1) | BR112019027366A2 (es) |
CA (1) | CA3068157A1 (es) |
GB (1) | GB2581876B (es) |
IL (2) | IL271596B2 (es) |
MX (2) | MX2019015927A (es) |
WO (1) | WO2018234871A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3117842A1 (en) * | 2018-10-26 | 2020-04-30 | Viramal Limited | Mucoadhesive gel composition |
ES2948955T3 (es) | 2018-11-30 | 2023-09-22 | Viramal Ltd | Un método de preparación de un agente gelificante, el agente gelificante obtenido de este modo y el uso de dicho agente gelificante |
WO2024163513A1 (en) * | 2023-01-30 | 2024-08-08 | Viramal Limited | Compositions for peritoneal drug delivery and methods of use thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4211769A (en) * | 1977-08-24 | 1980-07-08 | Takeda Chemical Industries, Ltd. | Preparations for vaginal administration |
JPH0735335B2 (ja) * | 1991-02-28 | 1995-04-19 | 五十嵐 正雄 | 子宮内膜症の治療薬 |
US5543150A (en) * | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
GB9426409D0 (en) * | 1994-12-30 | 1995-03-01 | Britannia Health Products Ltd | A composition for treating endometriosis |
US5993856A (en) | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
JP2000159689A (ja) * | 1998-11-26 | 2000-06-13 | Teikoku Hormone Mfg Co Ltd | 月経異常の処置又は予防剤 |
JP2005507874A (ja) | 2001-08-29 | 2005-03-24 | ユーエムディー, インコーポレイテッド | 癌治療のための化学療法剤及び膜流出システム阻害剤の経膣送達 |
US9211259B2 (en) * | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8529939B2 (en) * | 2003-12-08 | 2013-09-10 | Gel-Del Technologies, Inc. | Mucoadhesive drug delivery devices and methods of making and using thereof |
WO2006082596A2 (en) * | 2005-01-19 | 2006-08-10 | Kamalinder Kaur Singh | Neem oil contraceptive formulations |
US20070280972A1 (en) * | 2006-04-25 | 2007-12-06 | Zars, Inc. | Adhesive solid gel-forming formulations for dermal drug delivery |
GB2445539A (en) | 2006-12-29 | 2008-07-16 | Ardana Bioscience Ltd | Bigel composition |
WO2008089405A1 (en) * | 2007-01-19 | 2008-07-24 | Neurosci, Inc. | Composition of multiple hormones delivered vaginally in a single cream |
US20080287408A1 (en) * | 2007-05-14 | 2008-11-20 | Drugtech Corporation | Endometriosis treatment |
US8691248B2 (en) * | 2008-03-11 | 2014-04-08 | Mary Kay Inc. | Stable three-phased emulsions |
EP2174650A1 (en) | 2008-10-08 | 2010-04-14 | Polichem SA | Modified release emulsions for application to skin or vaginal mucosa |
WO2011121604A2 (en) * | 2010-03-29 | 2011-10-06 | Lincoln Pharmaceuticals Limited | A liquid vaginal spray formulation for treatment of vaginal fungal infection |
DK2648742T3 (da) * | 2010-12-09 | 2019-07-15 | Y&B Mothers Choice Ltd | Formuleringer indeholdende saponiner og anvendelser deraf |
IL215224A0 (en) * | 2011-09-18 | 2012-02-29 | Katz Daniel Dr | Vaginal danazol combined with non steroidal anti inflammatory drugs (nsaids) compositions |
WO2014026707A1 (en) * | 2012-08-13 | 2014-02-20 | Edko Pazarlama Tanitim Ticaret Limited Sirketi | Anti-vaginitis compositions with improved release and adherence |
US20180360769A1 (en) * | 2015-11-30 | 2018-12-20 | Elliptical Therapeutics, Llc | Systems and methods for transdermal drug delivery |
CA3010829A1 (en) * | 2016-01-07 | 2017-07-13 | Viramal Limited | Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof |
-
2018
- 2018-06-22 JP JP2019570825A patent/JP7345398B2/ja active Active
- 2018-06-22 CA CA3068157A patent/CA3068157A1/en active Pending
- 2018-06-22 IL IL271596A patent/IL271596B2/en unknown
- 2018-06-22 CN CN201880054903.4A patent/CN111386129A/zh active Pending
- 2018-06-22 GB GB2000586.4A patent/GB2581876B/en active Active
- 2018-06-22 EP EP18760000.2A patent/EP3641821A2/en active Pending
- 2018-06-22 BR BR112019027366-2A patent/BR112019027366A2/pt unknown
- 2018-06-22 KR KR1020207002137A patent/KR20200019735A/ko not_active Application Discontinuation
- 2018-06-22 IL IL310755A patent/IL310755A/en unknown
- 2018-06-22 US US16/624,597 patent/US20200121589A1/en active Pending
- 2018-06-22 MX MX2019015927A patent/MX2019015927A/es unknown
- 2018-06-22 WO PCT/IB2018/000807 patent/WO2018234871A2/en unknown
- 2018-06-22 AU AU2018287513A patent/AU2018287513A1/en active Pending
-
2019
- 2019-12-20 MX MX2023006235A patent/MX2023006235A/es unknown
-
2023
- 2023-05-11 JP JP2023078658A patent/JP2023090986A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL310755A (en) | 2024-04-01 |
IL271596B2 (en) | 2024-07-01 |
JP2020524690A (ja) | 2020-08-20 |
WO2018234871A2 (en) | 2018-12-27 |
BR112019027366A2 (pt) | 2020-08-18 |
JP2023090986A (ja) | 2023-06-29 |
WO2018234871A3 (en) | 2019-04-25 |
EP3641821A2 (en) | 2020-04-29 |
GB2581876A (en) | 2020-09-02 |
MX2023006235A (es) | 2023-06-15 |
CN111386129A (zh) | 2020-07-07 |
GB2581876B (en) | 2023-05-31 |
IL271596A (en) | 2020-02-27 |
KR20200019735A (ko) | 2020-02-24 |
GB202000586D0 (en) | 2020-02-26 |
CA3068157A1 (en) | 2018-12-27 |
IL271596B1 (en) | 2024-03-01 |
US20200121589A1 (en) | 2020-04-23 |
AU2018287513A1 (en) | 2020-02-06 |
JP7345398B2 (ja) | 2023-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
MY192084A (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
MX2018015892A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
SA520411119B1 (ar) | تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها | |
MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
MX2017015879A (es) | Composiciones de hidroxipropil beta-ciclodextrina y metodos. | |
PH12016502352A1 (en) | Pharmaceutical composition | |
TW201613578A (en) | Pharmaceutical combinations | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
MX2023006235A (es) | Composiciones para administracion de farmacos y metodos de uso de las mismas. | |
PH12019500328A1 (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
EA201692298A1 (ru) | Производные карбоксамидов | |
BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
EP4234021A3 (en) | Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy | |
PH12019500327A1 (en) | Indazole compounds for use in tendon and/or ligament injuries | |
WO2016030899A8 (en) | Methods of treating amyotrophic lateral scleroses | |
IL250852B (en) | Periodontal preparation | |
MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
EA201991817A1 (ru) | Интраназальная композиция, включающая бетагистин | |
MA39009A (fr) | Compositions pharmaceutiques comprenant un agent actif | |
EA202190247A1 (ru) | ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ |